Private Advisor Group LLC Purchases 2,255 Shares of Insulet Co. (NASDAQ:PODD)

Private Advisor Group LLC boosted its position in Insulet Co. (NASDAQ:PODD) by 30.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,642 shares of the medical instruments supplier’s stock after purchasing an additional 2,255 shares during the quarter. Private Advisor Group LLC’s holdings in Insulet were worth $2,517,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its position in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after buying an additional 42 shares during the period. Nisa Investment Advisors LLC boosted its stake in Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after acquiring an additional 43 shares in the last quarter. Glenmede Trust Co. NA grew its holdings in Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares during the period. Graypoint LLC increased its stake in shares of Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock valued at $140,000 after purchasing an additional 47 shares during the last quarter.

Insulet Stock Up 0.2 %

PODD stock opened at $283.48 on Tuesday. The company has a market cap of $19.88 billion, a price-to-earnings ratio of 48.96, a P/E/G ratio of 3.62 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The business’s 50-day moving average is $273.33 and its two-hundred day moving average is $248.46. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PODD shares. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Stifel Nicolaus lifted their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday. StockNews.com upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Monday. Citigroup raised their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wells Fargo & Company upped their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus target price of $289.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.